Preoperative versus postoperative docetaxel–cisplatin–fluorouracil (TCF) chemotherapy in locally advanced resectable gastric carcinoma: 10-year follow-up of the SAKK 43/99 phase III trial

Fazio, Nicola; Biffi, Roberto; Maibach, Rudolf; Hayoz, Stefanie; Thierstein, Sandra; Brauchli, Peter; Bernhard, J.; Stupp, Roger; Andreoni, B.; Renne, Giuseppe; Crosta, C.; Morant, Rudolf; Chiappa, A.; Luca, Fabrizio; Zampino, Maria Giulia; Huber, Olivier; Goldhirsch, A.; Braud, Filippo de; Roth, Arnaud; Pace, Ugo; Cenciarelli, Sabine; Pozzi, Samantha; Bertani, Emilio; Mura, Silvia; Lorizzo, Katia; Meglio, Giovanni Di; Ravizza, Davide; Boselli, Sabrina; Matter, Maurice; Richter, M.; Monfardini, S.; Dittrich, Christian; Häfner, Matthias; Clemens, Michael

doi:10.1093/annonc/mdv620

Cited by 42 publications

(19 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…90.7%, respectively) ( 6 ). In the Swiss group for clinical cancer research (SAKK) trial, almost all patients (33/34) started NACT, whereas one-third patients (12/35) did not even start chemotherapy in the ACT arm ( 17 ). Body weight loss after surgery was found to be an independent risk factor for continuation of S-1 ACT ( 18 ).…”

Section: Discussionmentioning

confidence: 99%

Oxaliplatin plus S-1 or capecitabine as neoadjuvant or adjuvant chemotherapy for locally advanced gastric cancer with D2 lymphadenectomy: 5-year follow-up results of a phase II−III randomized trial

Xue

Ying

et al. 2018

Chinese Journal of Cancer Research

View full text Add to dashboard Cite

ObjectiveTo compare the effect of neoadjuvant chemotherapy (NACT) with adjuvant chemotherapy (ACT) using oxaliplatin plus S-1 (SOX) or capecitabine (CapeOX) on gastric cancer patients with D2 lymphadenectomy.MethodsThis was a two-by-two factorial randomized phase II−III trial, and registered on ISRCTN registry (No. ISRCTN12206108). Locally advanced gastric cancer patients were randomized to neoadjuvant SOX, neoadjuvant CapeOX, adjuvant SOX, or adjuvant CapeOX arms. Primary analysis was performed on an intention-to-treat (ITT) basis using overall survival (OS) as primary endpoint.ResultsThis trial started in September 2011 and closed in December 2012 with 100 patients enrolled. Treatment completion rate was 56%, 52%, 38% and 30% in the four arms, respectively. NACT group had fewer dropouts due to unacceptable toxicity (P=0.042). Surgical complication rate did not differ by the four groups (P=0.986). No survival significant difference was found comparing NACT with ACT (P=0.664; 5-year-OS: 70% vs. 74% respectively), nor between the SOX and CapeOX groups (P=0.252; 5-year-OS: 78% vs. 66% respectively). Subgroup analysis showed SOX significantly improved survival in patients with diffuse type (P=0.048). ConclusionsNo significant survival difference was found between NACT and ACT. SOX and CapeOX had good safety and efficacy as neoadjuvant regimens. Diffuse type patients may survive longer due to SOX.

show abstract

Section: Discussionmentioning

confidence: 99%

Oxaliplatin plus S-1 or capecitabine as neoadjuvant or adjuvant chemotherapy for locally advanced gastric cancer with D2 lymphadenectomy: 5-year follow-up results of a phase II−III randomized trial

Xue

Ying

et al. 2018

Chinese Journal of Cancer Research

View full text Add to dashboard Cite

show abstract

“…The standard first-line treatment for mGC can slow disease progression and improve overall survival. New clinical evidence shows that some patients can benefit from secondary rescue chemotherapy [ 4 - 8 , 22 ]. But for those who fail rescue treatment, there are a lack of effective treatments.…”

Section: Discussionmentioning

confidence: 99%

Multicenter phase II study of apatinib treatment for metastatic gastric cancer after failure of second-line chemotherapy

et al. 2017

View full text Add to dashboard Cite

Apatinib is a tyrosine kinase inhibitor and vascular endothelial growth factor receptor 2 (VEGFR-2) targeted drug. A phase I clinical trial showed that this agent has antitumor activity in Chinese patients with metastatic gastric cancer (mGC). The aim of this study was to investigate the safety and efficacy of apatinib treatment in patients with mGC.This was an open-label, multicenter, single-arm study involving four institutions in China. We enrolled 42 patients from March 2015 to October 2015 who experienced tumor progression after second-line chemotherapy and had no other treatment options that clearly conferred a survival benefit. Oral apatinib (850 mg daily) was administered within 30 min of eating breakfast, lunch, or dinner on days 1 through 28 of each 4-week cycle.The median progression-free survival (PFS) time and median overall survival (OS) time were 4.0 months (95% CI, 2.85-5.15) and 4.50 months (95% CI, 4.03-4.97), respectively. The disease control rate (DCR) and objective response rate (ORR) were, respectively, 78.57% and 9.52% after 2 cycles and 57.14% and 19.05% after 4 cycles. The main adverse events (AEs) were secondary hypertension, elevated aminotransferase, and hand-foot syndrome, with incidences of 35.71%, 45.24%, and 40.48%, respectively. The most common grade 3 to 4 AEs were secondary hypertension and elevated aminotransferase, with incidences of 7.14% each.Apatinib is effective and safe in heavily pretreated patients with mGC who fail to respond to two or more prior chemotherapy regimens. Toxicities were tolerable or could be clinically managed.

show abstract

“…4 Chemotherapy becomes the prioritized surgical approach for advanced GC patients, but only serve the purpose of palliative treatment as GC is too difficult to cure. 5 Clinically, oxaliplatin combined with 5-fluorouracil and folinic acid (FOLFOX) is an effective chemotherapy regimen for patients with advanced GC. 6 However, GC is a kind of malignant tumor with strong heterogeneity, whose primary or acquired drug resistance prevent chemotherapy from completely destroying the tumor cells, while chemotherapy insensitivity is a common cause of tumor recurrence and metastasis.…”

Section: Introductionmentioning

confidence: 99%

<p>Serum miR-191 and miR-425 as Diagnostic and Prognostic Markers of Advanced Gastric Cancer Can Predict the Sensitivity of FOLFOX Chemotherapy Regimen</p>

Bie¹,

Li²,

Deng³

et al. 2020

OTT

View full text Add to dashboard Cite

Purpose: miR-191 and miR-425 have been proved to be highly expressed in gastric carcinoma (GC). However, little research has been done on their clinical value in serum of patients with advanced GC. In addition, it is not clear whether they can be used as markers for the response and prognosis of GC patients treated with oxaliplatin combined with 5-fluorouracil and FOLFOX chemotherapy. Patients and Methods: A total of 230 patients with advanced GC admitted to our hospital were selected as the study objects, all of whom received FOLFOX chemotherapy regimen. Another 100 cases of healthy subjects were included. QRT-PCR was employed to detect the serum expression of miR-191 and miR-425 in patients. Results: Compared with the healthy subjects, the serum expressions of miR-191 and miR-425 in GC patients were significantly upregulated, which were correlated with differentiation degree and TNM staging, respectively. According to the ROC curve, the AUC of miR-191 and miR-425 for GC diagnosis was 0.937 and 0.901, respectively, while the AUC for differentiation degree diagnosis was 0.854 and 0.822, and that for TNM staging diagnosis was 0.860 and 0.829, respectively. The predictive AUC of miR-191 and miR-425 for chemosensitivity was 0.868 and 0.835, respectively, with a combined predictive AUC of 0.935. Low differentiation degree, high TNM staging, high miR-191 and high miR-425 expressions were independent risk factors for chemotherapy insensitivity. Differentiation degree, TNM staging, chemotherapy effect, miR-191 and miR-425 were independent influencing factors for the prognosis of GC patients. Conclusion: Up-regulated expression of miR-191 and miR-425 in the serum of patients with advanced GC are effective biomarkers for the diagnosis, chemotherapy and prognosis evaluation of GC.

show abstract

Preoperative versus postoperative docetaxel–cisplatin–fluorouracil (TCF) chemotherapy in locally advanced resectable gastric carcinoma: 10-year follow-up of the SAKK 43/99 phase III trial

Cited by 42 publications

References 23 publications

Oxaliplatin plus S-1 or capecitabine as neoadjuvant or adjuvant chemotherapy for locally advanced gastric cancer with D2 lymphadenectomy: 5-year follow-up results of a phase II−III randomized trial

Oxaliplatin plus S-1 or capecitabine as neoadjuvant or adjuvant chemotherapy for locally advanced gastric cancer with D2 lymphadenectomy: 5-year follow-up results of a phase II−III randomized trial

Multicenter phase II study of apatinib treatment for metastatic gastric cancer after failure of second-line chemotherapy

<p>Serum miR-191 and miR-425 as Diagnostic and Prognostic Markers of Advanced Gastric Cancer Can Predict the Sensitivity of FOLFOX Chemotherapy Regimen</p>

Contact Info

Product

Resources

About